People · Operator
Named in public records as an officer, director or promoter · active 2014–2021 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| XTuit Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $39.5M | $748.7M | 2014 |
| polySpectra, Inc. | — | Other Technology | Series A | $8.4M | $19.7M | 2021 |
Rakesh Jain at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rakesh Jain on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| David Mott | 1 | 9 |
| Alan Crane | 1 | 9 |
| Dakin Sloss | 1 | 9 |
| Brandon Simmons | 1 | 5 |
| Garry Nicholson | 1 | 3 |
| Edward Freedman | 1 | 3 |
| Raymond Weitekamp | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.